Clinical Scorecard: Pericardial Complications Linked to Bruton Tyrosine Kinase Inhibitors: Comparisons by Agent and Generation

At a Glance

Key Highlights

• Among 575 patients, 34 (5.9%; 95% CI, 4.1%-8.2%) experienced incident pericardial effusion or cardiac tamponade; the rate was 1.9 events per 100 person-years.

• Three patients (0.5%) had cardiac tamponade; all had received ibrutinib. Pericarditis was reported in 7 patients (1.2%).

• Adjusted analysis did not identify an association between newer-generation BTKis and the primary outcome compared with ibrutinib (HR, 0.82; 95% CI, 0.38-1.78).

• Agent-specific adjusted hazard ratios versus ibrutinib were imprecise, and the study authors stated that available data could not establish whether risk varied by agent or generation.

• Patients with events were older and more frequently had coronary artery disease in descriptive, unadjusted comparisons.

Guideline-Based Recommendations

Diagnosis

• The study identified incident pericardial effusion or cardiac tamponade from routine-care clinical notes and echocardiographic reports; it did not use protocolized surveillance.

Management

• The study did not evaluate or recommend a specific management strategy for pericardial effusion or cardiac tamponade.

Monitoring & Follow-up

• The study did not evaluate or recommend a specific monitoring schedule.

Risks

• The authors noted that clinically indicated echocardiography could have missed asymptomatic effusions and events treated outside the Mayo Clinic system.

• Newer-generation BTKis had shorter follow-up, and the small number of events limited agent-specific inference.

Patient & Prescribing Data

The cohort included 575 adults (median age 77 years; 70.6% male) treated with a BTKi and without documented pericardial disease or effusion before initiation.

Treatment groups were ibrutinib (331), acalabrutinib (122), zanubrutinib (85), and pirtobrutinib (37). Event proportions were 7.3%, 3.3%, 5.9%, and 2.7%, respectively; adjusted comparisons did not establish differences by agent.

Clinical Best Practices

• The authors note that treatment selection may have reflected clinical and treatment factors, limiting interpretation of observational agent and generation comparisons.

• Event ascertainment relied on routine-care documentation rather than protocolized echocardiographic surveillance.

• Age, coronary artery disease, heart failure, and anticoagulant-use comparisons between patients with and without events were descriptive and unadjusted.

Related Resources & Content

1. ASCO Publications, 2023 — Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis

2. American College of Cardiology, 2026 — Cardio-Oncology Concise Clinical Guidance Key Takeaways

3. JAMA Oncology, 2026 — Pericardial Effusion and Bruton Tyrosine Kinase Inhibitors in B-Cell Malignant Disease

4. ASCO Publications — Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis.

5. ASCO Publications — Cardiovascular adverse events associated with second generation Bruton tyrosine kinase inhibitor therapy: A systematic review and meta-analysis.

6. ASCO Publications — Risk assessment of cardiovascular adverse events with BTK inhibitors in hematological malignancies: Insights from FAERS.

7. American College of Cardiology Cardio-Oncology Concise Clinical Guidance Key Takeaways

8. Pericardial Effusion and Bruton Tyrosine Kinase Inhibitors in B-Cell Malignant Disease